Bioanalysis special focus issue on antibody-drug conjugates

Bioanalysis

Volumn 5, Issue 9, 2013, Pages 981-983

  Kaur, Surinder ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; BRENTUXIMAB VEDOTIN; DRUG ANTIBODY; TRASTUZUMAB EMTANSINE;

ANTIBODY DETECTION; BREAST CANCER; DNA ADDUCT; DRUG CLEARANCE; DRUG CONJUGATION; HODGKIN DISEASE; HUMAN; IMMUNOGENICITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL ASSAY; CHROMATOGRAPHY, LIQUID; HUMANS; IMMUNOCONJUGATES; MASS SPECTROMETRY; NEOPLASMS;

EID: 84877291502     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.68     Document Type: Review

References (12)

1. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367(19), 1783-1791 (2012).
2. Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin. Cancer Res. 17(20), 6389-6397 (2011).
3. Thevanayagam L, Bell A, Chakraborty I et al. Novel detection of DNA-alkylated adducts of antibody-drug conjugates with potentially unique preclinical and biomarker applications Bioanalysis 5(9), 1073-1081 (2013).
4. Xu K, Liu L, Dere R et al. Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum Bioanalysis 5(9), 1057-1071 (2013).
5. Hoofring SA, Lopez R, Hock MB et al. Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates. Bioanalysis 5(9), 1041-1055 (2013)
6. Dere RC, Yi J-H, Lei C et al. PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. Bioanalysis 5(9), 1025-1040 (2013).
7. Carrasco-Triguero M, Yi J-H, Dere R et al. Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. Bioanalysis 5(9), 1007-1023 (2013).
8. Gorovits B, Alley SC, Bilic S et al. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis 5(9), 997-1006 (2013).
9. Kaur S, Xu K, Saad O et al. A perspective on bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis 5(2), 201-226 (2013).
10. Shen BQ, Xu K, Liu L et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody conjugates. Nat. Biotechnol. 30(2), 184-189 (2012).
11. US FDA (2011), Adcetris® approval. www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm268781.htm
12. US FDA (2013), Kadcyla® approval. www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm340704.htm